Provexis plc (FRA:NZCA)

Market Cap	27.91M +40.2%
Revenue (ttm)	998.17K -27.4%
Net Income	-691.75K
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0090
Previous Close	0.0090
Day's Range	0.0090 - 0.0090
52-Week Range	0.0005 - 0.0200
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 10, 2026

About Provexis

Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. The company offers syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and dietary supplement formats. It also provides Fruitflow+ Omega-3, a dietary supplement product. The company sells its products through e-commerce website ...

• Industry: Pharmaceutical Preparations
• Founded: 1999
• Employees: 2
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NZCA

Financial Performance

In fiscal year 2025, Provexis's revenue was 1.29 million, an increase of 61.13% compared to the previous year's 801,964. Losses were -452,720, -22.78% less than in 2024.

Financial numbers in GBP

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error